Weight LossInvestigational · Research use only
Orforglipron
LY3502970
Non-peptide, orally available small-molecule GLP-1 receptor agonist studied for obesity and type 2 diabetes without the food or water restrictions of oral semaglutide.
Metabolic
Class
Weight Loss / Metabolic
Targets
Loading research profile
Evidence
1 linked resource
Related
Eloralintide · Cagrilintide
★ Recommended Supplier
Get Orforglipron
Sourced from RUO. Third-party tested. COA available on request.
Buy Orforglipron — 10% OFF10% OFF off with codeMOLECULAR
[01]
Research overview
Benefits
- Oral GLP-1 activity
- Significant weight reduction
- Improved glycemic control
- No injection required
Research side effects
- Research-use only; safety data in healthy humans is limited or absent.
- Nausea / GI upset
- Appetite suppression
- Diarrhea or constipation
- GI upset
Timing
Often studied with or before meals; protocols vary by compound.
Common research stacks
Semaglutide
Tirzepatide
RETATRUTIDE
AOD-9604
5-Amino-1MQ
Cagrilintide
[06]
Trusted research partners
Partnered vendors we've verified sell this compound. Links go straight to the product page — use a member code at checkout.
[05]
Studies & resources
Research reference only · Review source material independently · Not medical advice